Over the past few decades, antibody-based therapies have revolutionized modern medicine and are now widely used to treat cancer, autoimmune diseases, inflammatory disorders and even infectious diseases. Despite their success, ...
Sep 13, 2026
0
34
What makes the brain fall asleep? For nearly a century, scientists have looked to structures deep within the brain for the answer. In the traditional view, these regions control when we sleep and wake, while the cerebral ...
Sep 13, 2026
0
79
Researchers at Vanderbilt Health, UTHealth Houston and the University of North Carolina at Chapel Hill have identified early signs of cardiovascular-kidney-metabolic disease (CKMD) in children as young as 8 years old that ...
Sep 13, 2026
0
21
When women take part in breast cancer screening, they are informed that screening may detect cancers that would never have caused symptoms or problems during their lifetime. This is known as overdiagnosis.
Sep 13, 2026
0
165
Researchers have found a high level of agreement between cataract referral decisions based on smartphone images reviewed remotely and those made by ophthalmologists examining patients in person at rural eye camps.
Sep 13, 2026
0
221
New results from the global phase 1/2 ARROS-1 trial showed clinically meaningful activity with zidesamtinib in patients with advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC) who had not previously received ...
Sep 13, 2026
0
7
Results from the phase 3 PAPILLON study show that first-line amivantamab plus carboplatin-pemetrexed (amivantamab-chemotherapy) was associated with numerically longer overall survival compared with chemotherapy in patients ...
Sep 13, 2026
0
5
An international research team that included Martín Hugo, a Serra Húnter lecturer in the Department of Biochemistry and Molecular Biology at the UAB, has described how two opposing chemical modifications of proteins, sulfenylation ...
Sep 13, 2026
0
5
An exploratory 8-year landmark update from the Phase III ADAURA trial showed that adjuvant osimertinib continued to provide a long-term overall survival benefit for patients with completely resected, EGFR-mutated stage IB–IIIA ...
Sep 13, 2026
0
3
First-line treatment with trastuzumab deruxtecan (T-DXd) significantly improved progression-free survival compared with pembrolizumab plus platinum-based chemotherapy in patients with advanced or metastatic HER2-mutant non-small ...
Sep 13, 2026
0
3
